Retrospective Cohort Study of Safety Outcomes Associated with Opioid Rotations to Buprenorphine

References

• Dahan A, Yassen A, Bijl H, Romberg R, Sarton E, Teppema L, Olofsen E, Danhof M. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth. 2005;94(6):825–34. Epub 2005 Apr 15. PMID: 15833777. doi:10.1093/bja/aei145.
   PubMed Web of Science ®Google Scholar
• Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994;55(5):569–80. doi:10.1038/clpt.1994.71.
   PubMed Web of Science ®Google Scholar
• Cowan A. Update of the general pharmacology of buprenorphine. In: Cowan A, Lewis JW, editor. Buprenorphine: Combating drug abuse with a unique opioid. New York: Wiley-Liss, 1995, p. 31–47.
   Google Scholar
• Cowan A, Doxey JC, Harry EJ. The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br J Pharmacol. 1977;60(4):547–54. doi:10.1111/j.1476-5381.1977.tb07533.x.
   PubMedGoogle Scholar
• Doxey JC, Everitt JE, Frank LW, Mackenzie JE. A comparison of the effects of buprenorphine and morphine on the blood gases of conscious rats [abstract]. Br J Pharmacol. 1982;75:118P.
   Google Scholar
• Kishioka S, Paronis CA, Lewis JW, Woods JH. Buprenorphine and methoclocinnamox: agonist and antagonist effects on respiratory function in rhesus monkeys. Eur J Pharmacol. 2000;391(3):289–97. doi:10.1016/s0014-2999(00)00039-x.
   PubMedGoogle Scholar
• Dahan A, Yassen A, Romberg R, Sarton E, Teppema L, Olofsen E, Danhof M. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth. 2006;96(5):627–32. Epub 2006 Mar 17. PMID: 16547090. doi:10.1093/bja/ael051.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. Medications for opioid use disorder. treatment improvement protocol (TIP) series 63. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2020. [accessed 2023 Jan 21]. https://store.samhsa.gov/sites/default/files/pep21-02-01-002.pdf.
   Google Scholar
• VA/DoD clinical practice guideline for the management of substance use disorder version 3.0. Washington (DC): The Management of Substance Use Disorders Workgroup, Department of Veterans Affairs, Department of Defense; 2015. [accessed 2023 Jan 21]. https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPGFinal1.pdf.
   Google Scholar
• VA Pharmacy Benefits Management Services, Medical Advisory Panel and VISN Pharmacist Executives; National Mental Health Office – Substance Use Disorders; National Pain Management Strategy Coordinating Committee. Buprenorphine formulations for chronic pain management in patients with opioid use disorder or on long-term opioid therapy with physiologic tolerance: Department of Veterans Affairs; Oct. 2022. [accessed 2023 Jan 21]. https://www.va.gov/formularyadvisor/DOC_PDF/CRE_Buprenorphine_Formulations_for_Pain_Management_RFU_Rev_Oct_2022.pdf.
   Google Scholar
• Webster L, Gudin J, Raffa RB, Kuchera J, Rauck R, Fudin J, Adler J, Mallick-Searle T. Understanding buprenorphine for use in chronic pain: Expert opinion. Pain Med. 2020;21(4):714–23. doi:10.1093/pm/pnz356.
   PubMed Web of Science ®Google Scholar
• Zedler B, Xie L, Wang L, Joyce A, Vick C, Brigham J, Kariburyo F, Baser O, Murrelle L. Development of a risk index for serious prescription opioid-induced respiratory depression. Pain Med. 2015;16(8):1566–79. doi:10.1111/pme.12777.
   PubMed Web of Science ®Google Scholar
• Zedler B, Saunders W, Joyce A, et al. Validation of a screening risk index for overdose or serious prescription opioid-induced respiratory depression prescription opioid use and deaths from overdose or opioid-induced respiratory depression. Presented at the 2015 AAPM Annual Meeting, March 2015. http://paindr.com/wp-content/uploads/2015/12/FINAL-RIOSORD-AAPM-Poster-2-sided-3.pdf.
   Google Scholar
• Zedler BK, Saunders WB, Joyce AR, Vick CC, Murrelle EL. Validation of a screening risk index for serious prescription opioid-induced respiratory depression or overdose in a US commercial health plan claims database. Pain Med. 2018;19(1):68–78. PMID: 28340046; PMCID: PMC5939826. doi:10.1093/pm/pnx009.
   PubMed Web of Science ®Google Scholar
• Muzzio K, Chandler M, Painter JT, Dragic L. Characterizing patients after opioid taper in a VA medical center. J Pain Palliat Care Pharmacother. 2021;35(2):84–90. Epub 2021 May 6. PMID: 33956566. doi:10.1080/15360288.2021.1900492.
   PubMedGoogle Scholar
• Patel S, Carmichael JM, Taylor JM, Bounthavong M, Higgins DT. Evaluating the impact of a clinical decision support tool to reduce chronic opioid dose and decrease risk classification in a veteran population. Ann Pharmacother. 2018;52(4):325–31. Epub 2017 Oct 31. PMID: 29086587. doi:10.1177/1060028017739388.
   PubMedGoogle Scholar
• Tognoli E, Proto PL, Motta G, Galeone C, Mariani L, Valenza F. Methadone for postoperative analgesia: contribution of N-methyl-D-aspartate receptor antagonism: A randomised controlled trial. Eur J Anaesthesiol. 2020;37(10):934–43. PMID: 32516227. doi:10.1097/EJA.0000000000001217.
   PubMedGoogle Scholar
• Ebert B, Andersen S, Krogsgaard-Larsen P. Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett. 1995;187(3):165–8. PMID: 7624018. doi:10.1016/0304-3940(95)11364-3.
   PubMed Web of Science ®Google Scholar
• Sotgiu ML, Valente M, Storchi R, Caramenti G, Biella GE. Cooperative N-methyl-D-aspartate (NMDA) receptor antagonism and mu-opioid receptor agonism mediate the methadone inhibition of the spinal neuron pain-related hyperactivity in a rat model of neuropathic pain. Pharmacol Res. 2009;60(4):284–90. Epub 2009 Apr 11. PMID: 19717013 doi:10.1016/j.phrs.2009.04.002.
   PubMed Web of Science ®Google Scholar
• Hanna V, Senderovich H. Methadone in pain management: a systematic review. J Pain. 2021;22(3):233–45. Epub 2020 Jun 26. PMID: 32599153. doi:10.1016/j.jpain.2020.04.004.
   PubMedGoogle Scholar
• McNicol ED, Ferguson MC, Schumann R. Methadone for neuropathic pain in adults. Cochrane Database Syst Rev. 2017;5(5):CD012499. PMID: 28514508; PMCID: PMC6353163. doi:10.1002/14651858.CD012499.pub2.
   PubMedGoogle Scholar
• Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. MMWR Recomm Rep. 2016;65(1):1–49. doi:10.15585/mmwr.rr6501e1.
   PubMed Web of Science ®Google Scholar